Companies / Switzerland
Novartis Has Heart Set On Vaccines
July 2007 | Industry NewsNovartis - formed in 1996 through the merger of two Swiss drug firms Sandoz and Ceiba-Geigy - is the largest drugmaker in Switzerland, leading rival Roche by around US$5bn in annual sales. Growth has been strong over the past decade, propelled by an increased focus on healthcare and especially innovative pharmaceuticals. Since 2000, Novartis has gained US FDA approval for 15 new molecular entities (NMEs), more than any other major research-based multinational, and growth in 2006 was largely driven by two of its home-grown drugs. Hypertension treatment Diovan (valsartan) had sales of US$4.2bn and is the world's leading angiotensin receptor
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
